Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Duct Carcinoma of Breast
DRUG: Paclitaxel, Cisplatin|DRUG: EC to docetaxel or paclitaxel
Number of Participants With Disease-Free Survival (DFS) Events, DFS is defined as the time period between registration and first event, up to 5 year follow up
Number of Participants With Overall Survival (OS) Events, OS is defined as the time period between registration and first event, up to 5 year follow up|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0., Descriptive statistics for the treatment will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped, 5 months during adjuvant therapy
In this trial, patients will be randomly assigned in a 2:1 ratio to receive cisplatin-based adjuvant chemotherapy and to standard adjuvant chemotherapy.